Navigation Links
Mail-Order Pharmacy for New Statin Prescriptions Achieve Better Cholesterol Control in First 3-15 Months of Therapy
Date:7/21/2011

OAKLAND, Calif., July 21, 2011 /PRNewswire/ -- Kaiser Permanente Northern California patients who obtained new statin prescriptions via a mail-order pharmacy achieved better cholesterol control in the first 3-15 months following the initiation of therapy -- compared to those patients who only obtained their statin prescription from their local Kaiser Permanente Northern California pharmacy.

Greater adjusted rates of LDL-C control in mail-order pharmacy users were seen across all gender and race-ethnicity groups, according to the study that appears in the current online issue of the Journal of General Internal Medicine.

After adjustment for demographic, clinical, and socioeconomic characteristics, as well as for potential unmeasured differences between mail-order and in-person pharmacy users, 85 percent of patients who used the mail-order pharmacy achieved target cholesterol levels, compared to 74.2 percent of patients who only used the local Kaiser Permanente pharmacy.

Previous studies have shown that mail-order pharmacy use is associated with greater medication adherence. However, this is the first study to examine whether mail-order pharmacy use is related to improved cardiovascular risk factor outcomes, according to Julie Schmittdiel, PhD, an investigator with the Kaiser Permanente Division of Research in Oakland, Calif., and the lead author of the study.

"While the findings of this study should be confirmed in a randomized controlled trial, they provide new evidence that mail-order pharmacy use may be associated with improved care and outcomes for patients for risk factors with cardiovascular disease," Schmittdiel said.

"Though mail order may not be right for all patients, this study shows that it is one possible tool in the broader health care system-level toolbox that can help patients meet their medication needs."

At Kaiser Permanente, members have 24/7 access to online pharmacy and pharmacy refills at kp.org using My Health Manager, which can be mailed to them free of shipping charges or made available for pick-up at any Kaiser Permanente pharmacy.

In comparing the effectiveness of mail-order pharmacy vs. local pharmacy use on cholesterol control in new statin users, investigators tapped a study population of 100,298 Kaiser Permanente members who were statin users between Jan. 1, 2005, and Dec. 31, 2007.  Statin use was obtained from automated pharmacy records and patients were considered to be new users if they had not recorded use of statin in records prior to the initial statin prescription date.

Greater adherence to these medications by mail-order pharmacy users may reflect improved access to medications, researchers explain.  Mail order does not require travel to the local pharmacy, which may provide ease and convenience for patients refilling medications.  To address possible selection biases – for example, the possibility that patients who use mail-order pharmacy services are more motivated to take care of their health than patients who do not use such services – researchers conducted  additional analyses to minimize such biases. All analyses, even those accounting for such potential differences, showed a positive, significant association between mail order pharmacy use and cholesterol control.

This study is part of an ongoing body of work analyzing the impact of mail-order pharmacy use on clinical outcomes, and seeks to further understand how health care systems can work with patients to optimize medication use without compromising patient choice or safety.

In a January 2010 study in the American Journal of Managed Care, researchers from UCLA and the Kaiser Permanente Division of Research found that patients with diabetes, high blood pressure or high cholesterol who ordered their medications by mail were more likely to take them as prescribed by their doctors than did patients who obtained them from the local pharmacy.

Additional authors on the Journal of General Internal Medicine study include Andrew J. Karter, PhD;  Wendy Dyer, MS; Melissa Parker, MS; and Connie Uratsu, all with the Kaiser Permanente Division of Research.   James Chan, PharmD, PhD, with the Kaiser Permanente Pharmacy Outcomes and Research Group, and O.Kenrik Duru, MD, MSHS, with the UCLA David Geffen School of Medicine, also are co-authors.  Funding was provided by the Centers for Disease Control and Prevention (Division of Diabetes Translation) and the National Institute of Diabetes and Digestive Kidney Diseases.  

About the Kaiser Permanente Division of Research (http://www.dor.kaiser.org/)

The Kaiser Permanente Division of Research conducts, publishes and disseminates epidemiologic and health services research to improve the health and medical care of Kaiser Permanente members and the society at large. It seeks to understand the determinants of illness and well-being and to improve the quality and cost-effectiveness of health care. Currently, DOR's 400-plus staff is working on more than 250 epidemiological and health services research projects.

About Kaiser Permanente

Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America's leading health care providers and not-for-profit health plans. Founded in 1945, our mission is to provide high-quality, affordable health care services to improve the health of our members and the communities we serve. We currently serve 8.8 million members in nine states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education and the support of community health. For more information, go to: www.kp.org/newscenter.


'/>"/>
SOURCE Kaiser Permanente
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DHL Global Mail Launches Specialized Shipping Service for Mail-Order Pharmacies
2. CVS/pharmacy Offers Flu Vaccinations in Over 4,000 Stores
3. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
4. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
5. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
6. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
7. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
8. RICE MEMORIAL HOSPITAL PHARMACY STAFF EXPERIENCES A 55% REDUCTION IN TIME SPENT MANAGING PATIENT-SPECIFIC MEDICATIONS USING OMNICELL SINGLEPOINTE SOLUTION
9. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
10. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
11. Cardinal Health Expands PET Nuclear Pharmacy Services to Support Clinical Drug Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... N.J. , Dec. 3, 2016  Findings ... and safety of CTL019, an investigational chimeric antigen ... (r/r) pediatric and young adult patients with B-cell ... during an oral session at the 58th American ... December 3, 4:00-5:30 p.m.). The global Phase II ...
(Date:12/2/2016)... bioLytical Laboratories, un líder mundial en test rápidos de ... Self Test , a los miembros de la Kenya Pharmaceutical Association. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ... (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue invitada por la Clinton ...
(Date:12/2/2016)... According to the latest market report ... Automated Endoscope Reprocessors: Single Basin Automated Endoscope Reprocessors Product Type ... and 2024 " the global automated endoscope reprocessors market was valued at US$ ... a CAGR of 7.2% during an eight-year forecast period 2016-2024, ... 2024. ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... in New York City, with long-time partners The Paul Foundation, on November 10, ...
(Date:12/4/2016)... ... 04, 2016 , ... "Pro3rd Displace is a set of ... displacement design elements," said Christina Austin - CEO of Pixel Film Studios. ... of design styles that include both left aligned and right aligned options for ...
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in global ... Institute’s 21st Drug & Medical Device Litigation Conference , taking place in New York ... who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and the ...
(Date:12/2/2016)... ... 02, 2016 , ... Advanced Inc., a leading provider of travel therapy and ... to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously ... financial and operational leadership experience to Advanced Inc. He began his career in finance ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs ... patients must find the one that works for them. When an inventor from Suisun ... that worked and decided to share it with others. , He developed a prototype ...
Breaking Medicine News(10 mins):